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e.2012.11Abstract Introduction: Lower extremity varicose vein is a common disease. Sclerotherapy can be
used to treat truncal varices of the superﬁcial venous system. This involves injecting a sclerosant
intraluminally in order to cause ﬁbrosis and eventual obliteration of the vein.
Objective: To demonstrate the efﬁcacy and safety of foam sclerotherapy in the treatment of great
saphenous reﬂux measured against patient clinical examination and duplex scanning.
Materials and methods: Fifty legs with varicose veins due to incompetent great saphenous vein were
treated with ultrasound guided sclerosing foam prepared according to the Tessari method by mixing
3% polidocanol solution (Aethoxysclerol) with air using 2 disposable syringes and a three way tap
producing high-quality micro-foam. Clinical examination and duplex scanning before and after the
treatment with a mean follow up of 6 months were done to every patient.
Results: An average of 10 ml of foam was required to close incompetent Great saphenous veins as
deﬁned by a reﬂux of more than 0.5 s documented by duplex scan. At the 6th month of follow up,
patients felt that their legs were treated successfully with resolution of symptoms and complete res-
olution in 96%.
Conclusion: Foam sclerotherapy is a safe and effective therapy in treating varicose veins with high
patient satisfaction and improvement in quality of life.
ª 2012 Production and hosting by Elsevier B.V. on behalf of Alexandria University Faculty of Medicine.1. Introduction
The deﬁnition of sclerosing foam (SF) is a mixture of gas and
liquid sclerosing solution (detergent type). The gas must beess: Vascular Surgery Depart-
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.003well tolerated or physiologic and the bubble size less than
100. The behavior of sclerosing foam is different when injected
compared to the action of a liquid solution.1
The use of air and a sclerosing drug in combination was de-
scribed in 1944 by Orbach2: the air-block technique. The scle-
rosing solution was added to air, by simply shaking the syringe
or the vial to produce large bubbles which had a high air: li-
quid ratio and with increased efﬁcacy only for smaller veins,
this method is not suitable for larger veins such as saphenous
trunks or larger tributaries because after injection of foam, the
air positioned itself along the upper side of the vein, impending
contact with the endothelium.
Further advancement came then from subsequent innova-
tion: Cabrera et al.3,4 published an article about the produc-
tion of a complex foam with CO2. Monfreux
5 described thelexandria University Faculty of Medicine.
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of a glass syringe. Mingo-Garcia6 developed a special device to
produce foam with compressed air, and Tessari7 presented an
original method of foam formation with two disposable syrin-
ges and a three way-tap. Frullini8 published a different method
to produce foam in a vial of sclerosing solution, provided that
the vial has a rubber cap, the method utilizes the turbulence ef-
fect that a disposable syringe and a relatively large connector
can create into the vial with a fast push on the piston.
2. Materials and methods
Fifty randomly selected legs of 50 patients suffering from var-
icosities of the great saphenous vein reﬂux were enrolled in this
study.
All patients were examined clinically and by duplex scan-
ning to assess both superﬁcial and deep venous systems. The
exclusion criteria were: Pregnancy, breast feeding, DVT,
known allergy to polidocanol solution (Aethoxysclerol) and
lack of mobility. Inclusion criteria for the study were truncal
incompetence in the great saphenous veins as deﬁned by a re-
ﬂux of more than 0.5 s documented by duplex scan.
A Tessari micro-foam technique was done using
Aethoxysclerol 3% in a ratio of 1 ml sclerosing solution to
4 ml air Fig. 1.
The foam was generated according to Tessari by using two
disposable syringes and a three-way tap. Up to 10 ml the foam
was produced from 2 ml of Aethoxysclerol 3% and 7.5 ml of
air with 20 passages through the tap. Patients are treated at
the operating room which is equipped with a color duplex
ultrasound and an adjustable examination board, which can
be tilted to 45. Firstly, the sapheno-femoral disconnection is
done by local inﬁltration. Then, the patient is placed in a tilted
position to facilitate puncture of the GSV. The planned punc-
ture site of the GSV is normally 3–5 cm below the knee. The
vein is punctured under ultrasound guidance with an 18G stan-
dard vascular access needle. A standard guide wire is inserted
into the GSV using the standard Seldinger technique.
A 5Fr. introducer sheath is advanced over the guide wire.
The dilator and guide wire are removed. The patient is tipped
back to a horizontal position and the leg is elevated by 30. We
placed the introducer tip 2 cm distally to the sapheno-femoralFigure 1 A Tessari micro-foam technique using two disposable
syringes and a three way tap.junction. This catheterization procedure aimed to induce a sig-
niﬁcant vasospasm in the vein in order to reduce the blood vol-
ume present in the vessel and thereby increase concentration
and vessel-wall contact of the sclerosing agent.
Sclerosant foam is now prepared and injected in the catheter.
Whenthe foamhasreachedthe introducer-tip thesheath is slowly
withdrawn with one hand, while injecting 5–10 ml of sclerosing
foam depending on the length of the treated vein segment. After
application of a sterile dressing at the puncture site, compression
stockingsareapplieduptothethigh.Thepatientwastheninstantly
mobilizedandaskedtowalkforﬁveminutes.
All legs are placed in (class 2) 30–40 mmHg graduated elas-
tic stocking for 2 weeks (1 week all the time and 1 week during
the day only).
Every patient is advised to:
[1] Avoid straining, strenuous physical activity or Valsalva
maneuver for the ﬁrst month because they may contrib-
ute to early recanalization.
[2] Avoid prolonged car or plane travel of more than 4 h
during the ﬁrst month after treatment to decrease the
incidence of the thromboembolic events.
All patients were reviewed for occurrence of complication:
the complications were classiﬁed as systemic (drug reaction-
transient cofusional status and visual disturbance) and local
(DVT, phlebitis, skin pigmentation, skin necrosis). Follow-up
was provided for every patient: every patient was reviewed at
1 week, 1 month, 3 months and 6 months by duplex and clini-
cal examinations as well as patient satisfaction.
3. Results
3.1. Safety
In 50 patients with GSV reﬂux, 50 limbs were studied (Table 1).
Subjects’ age ranged from 25 to 41 years with a mean of
33 years. Fifty-six percent were women and 44% were men.
Compared with the classic liquid sclerotherapy, foam scle-
rotherapy is more likely to induce post inﬂammatory hyperpig-
mentation but less likely to induce skin necrosis because it has
a much higher sclerosing power at a 3- to 4-fold dilution. A few
weeks following therapy, patients may experience a string-like
induration of the injected vein due to venous obliteration.
Adverse outcomes were infrequent with no serious complica-
tions reported. Any erythema was meticulously reported as
superﬁcial thrombophlebitis (STP) (2%) Fig. 2. Other adverse
effects reported or observed included pain along the course of
the great saphenous vein (6%), staining and hyper pigmentation
(36%) reﬂecting the aggressive treatment approach to complete
the closure of all branch varicosities and any demonstrated ve-
nous channels Fig. 3. There was no documented incidence of
anaphylaxis, stroke, sepsis, arterial injection, and nerve damage.
Because of ligation of SFJ, the sclerosing foamdoes not enter the
systemic circulation after administration, and neither deep vein
thromboses (DVTs) nor emboli have been reported.
3.2. Efﬁcacy
An average total volume of 7.3 mL foam (equivalent to 1.7 mL
of 3% polidocanol solution) was injected to achieve venous
Table 1 Anatomical CEAP classiﬁcation of cases studied (n= 50).
C0 No visible or palpable signs of venous insuﬃciency 0%
C1 Telangiectasia and/ or reticular varicosities 6%
C2 Varicose veins (VVs) 90%
C3 VVs with leg edema, or corona phlebectatica 0%
C 4 Venous eczema, pigmentation, lipodermatosclerosis, atrophie blanche 0%
C5 Healed varicose ulcers 4%
C6 Active venous ulceration 0%
CEAP, clinical, etiological, anatomical and pathological elements.
Figure 2 Two cases of STP 1 month after treatment of incompetent great saphenous vein with 10 ml of 3% polidocanol foam.
Figure 3 Staining and hyper pigmentation after foam
sclerotherapy.
Figure 4 Closed great saphenous vein one week after treatment.
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3 months, 18% required additional UGFS treatment, and
6% between 3 and 6 months (Table 2). Symptoms (92%) such
as aching limb pain and cramps resolved on the ﬁrst month of
treatment.
4. Discussion
4.1. Safety
In the 50 legs treated with sclerosing foam we had no serious
complications (in particular, no pulmonary embolism, no
DVT or nerve injury). Phlebitis which was a sequela of exces-
sive inﬂammatory reaction of the sclerosing foam had-oc-
curred in 2% of legs (two different patients), while Frullini
and Cavezzi9 and Rabee et al.10 reported only 1% of phlebitis.No skin necrosis, sclerosant induced ulcer, wound infection or
nerve injury was reported.
This study demonstrated a high patient satisfaction with
improvement of the quality of life and a high rate of closure
of the saphenous trunks and visible varicosities with foam
therapy.
Results achieved in this study were comparable with other
studies.11–14 But in the VEDICO trial comparing the treatment
of varicose veins using several techniques including sclerother-
apy, surgery and foam sclerotherapy, the study demonstrated
the elimination of reﬂux in all patients with 10 year follow
up.15
The incidence of passage of the foam to the deep system is
eliminated by ligation of the saphenofemoral junction. In Jan-
uary and November 2004, a study conducted by Barrett et al.16
showed similar results to our study. They used the same tech-
nique to obtain high success with low incidence of
complication.
Figure 5 Fibrotic great saphenous vein six months after
treatment.
Table 2 Duplex follow-up data after 6 months.
Location Success/occluded Partial success/
occluded
No success/
recanalized
GSV (n= 50) 47 (94%) 1 (2%) 2 (4%)
Table 3 Subgroup SFJ diameters over time (n= 50).
Initial diameter (mm) Month 1 Month 3 Month 6
CEAP 1 (6%) 4.6 3.3 2.9 1.5
CEAP2 (90%) 5.0 4.1 2.6 1.6
CEAP 5 (4%) 3 2.6 2.0 1.2
SFJ, saphenofemoral junction; CEAP, clinical, etiological, ana-
tomical and pathological elements.
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Compared with classic liquid sclerotherapy, foam sclerother-
apy was about four times more effective because of in-
creased contact time with the venous wall, increased
surface area of the venous wall, and venous spasm.1 After
one UGFS session, more than two thirds of the truncal var-
icosities were occluded and more than 90% of treatments
were successful after two or three sessions.17 Several large
case series and one multicenter study have been published.
UGFS in 1411 limbs showed occlusion in 88% of GSVs
after a mean follow-up of 11 months.17–19 Few studies
showed 69% complete sclerosis in 99 limbs after 24 months
of follow-up,12 44% occlusion in 211 limbs after 5 years of
follow-up,13 and 88% occlusion in 143 limbs after 6 weeks
of follow-up.14 A small prospective randomized trial
suggested that SFJ ligation and one session of UGFS was
less effective in the short term, but signiﬁcantly less
costly and time-consuming than stripping, and multiple
avulsions.15All sizes of GSVs over all CEAP classes were shown to be
safely and effectively treated (Table 3). Patients enjoyed an
immediate return to activity, avoiding the cost of time off
work. The technique of UGFS was well accepted by all pa-
tients, who felt strongly that UGFS was effective in treating
their varicose veins, would recommend it to a friend, and
would have UGFS repeated in the future if required. A statis-
tically signiﬁcant reduction in the diameter of the GSV was
demonstrated in all cases of GSV reﬂux.
Although most of the patients who needed further treat-
ment were during the ﬁrst 3 months of follow up, we believed
that the 6 month follow up provides a sufﬁcient time to assess
the development of early recanalization.20 Barrett et al.16 had
reported that, a 3 month follow up was enough but others11,16
did not accept that because this period was too short for estab-
lishment of alternative venous pathway.
Surgery carries a risk of general anesthesia and the time of
work off. Surgery is not more effective than foam sclero-therapy
for primary truncal saphenous vein treatment.18 So we believed
that, it was difﬁcult to justify a procedure that has increased pa-
tient morbidity and mortality and no increase in safety.
5. Conclusion
We believed that foam sclerotherapy is a safe and effective
treatment for varicose veins without serious side effects. It
can be used for varicosities due to saphenous trunk reﬂux. Pa-
tient safety is a prime indication for foam therapy (no general
anesthesia and low risk of DVT). Foam has added the beneﬁt
of high patient satisfaction, less hospital stay and early return
to the daily work.References
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